
|Articles|April 15, 2002
Comfort level of ocular allergy agent is key to patient compliance
San Antonio, TX-A treatment for seasonal allergic conjunctivitis, pemirolast potassium 0.1% ophthalmic solution (Alamast, Santen Inc., Napa, CA), was shown to be more comfortable for patients and equally effective when used twice a day during ragweed season when compared with nedocromil sodium 2% ophthalmic solution (Alocril, Allergan, Irvine, CA). These two drugs are the two latest mast-cell stabilizers that have become commercially available to treat ocular allergies.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
First patient treated in ViaLase’s IDE trial
2
Iolyx Therapeutics and Laboratoires Théa enter into agreement over ILYX-002 for the treatment of OSD
3
Formosa Pharmaceuticals and Rxilient sign licensing and commercialization agreement for APP13007
4
PainReform launches development plan for OcuRing-K, readies phase 2 trial
5















































.png)


